| Literature DB >> 33301993 |
Paul Tarteret1, Alessio Strazzulla2, Maxence Rouyer3, Cecile Gore4, Guillaume Bardin5, Coralie Noel6, Zine-Eddine Benguerdi4, Julien Berthaud7, Manuel Hommel7, Sylvie Aufaure4, Sebastien Jochmans8, Sylvain Diamantis2.
Abstract
OBJECTIVES: This study aimed to identify demographic, clinical and medical care factors associated with mortality in three nursing homes in France.Entities:
Keywords: Case fatality rate; Confinement disease; Standards of care
Mesh:
Year: 2020 PMID: 33301993 PMCID: PMC7721348 DOI: 10.1016/j.ijid.2020.12.004
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 3.623
Infection control and medical care organisation during the first 3 weeks of the outbreak.
| Characteristics | Home A (n = 66) | Home B (n = 162) | Home C (n = 147) |
|---|---|---|---|
| Hospital-dependent home | + | + | – |
| Permanent physician | 1 | 2 | 0 |
| Infection control practitioner | + | + | – |
| Conforming surface detergent | + | + | – |
| Isolation unit | – | + | – |
| Isolation in room | + | + | + |
| Adequate PPE stock | + | + | – |
| Adequate oxygen tank stock | + | + | – |
| Nurse reinforcement | 2 | 0 | 0 |
| 24-h nurses | – | + | – |
| Replacement if sick leave | + | + | – |
PPE, personal protective equipment.
Nursing home located nearby and being part of general hospital group.
Intervention by infection control practitioner during COVID-19 outbreak.
If detergent was conforming to the EN 14,476 European legislation.
If a specific COVID-19 area was created in the nursing home.
Figure 1Epidemiology in nursing homes during first 3 months of the outbreak.*.
*Onset of local epidemic (J0) defined as the day where the first confirmed COVID-19 case had his first symptom.
**Confirmed COVID-19 cases if residents had positive SARS-Cov2 PCR or if residents had positive SARS-Cov2 serology.
***Task force intervention took action from 09 to11 April 2020.
Outcome, clinical and medical care residents’ characteristics of hospital-dependent (Homes A and B) and non-hospital-dependent nursing homes (Home C) (n = 375).
| Characteristics | Hospital dependent (n = 228) | Non-hospital dependent (n = 147) | OR (95% CI) | |
|---|---|---|---|---|
| First 3-month outcomes | ||||
| All-cause death [n (%)] | 16 (7.0) | 41 (28.1) | 0.19 (0.10–0.36) | 0.001 |
| All-cause death for the same time frame one year before [n (%)] | 11 (4.8) | 6 (4.1) | 1.18 (0.42–1.27) | 0.74 |
| Death in COVID-19 presumed and confirmed cases [n (%)] | 15 (6.6) | 38 (25.8) | 0.20 (0.11–0.38) | 0.001 |
| Death in COVID-19 confirmed cases [n (%)] | 11 (4.8) | 11 (7.5) | 0.62 (0.26–1.48) | 0.28 |
| Confirmed COVID-19 cases | 96 (42.1) | 92 (63.0) | 0.43 (0.28–0.65) | 0.001 |
| Presumed COVID-19 cases | 9 (4.0) | 27 (18.5) | 0.17 (0.08–0.38) | 0.001 |
| First 3-week medical care management | ||||
| Daily clinical examination | 107 (46.9) | 7 (4.8) | 17.69 (7.93–39.46) | 0.001 |
| TID vital signs measurements | 64 (28.1) | 3 (2.0) | 18.63 (5.76–60.92) | 0.001 |
| Prophylactic anticoagulation | 28 (12.3) | 12 (8.2) | 1.57 (0.78–3.31) | 0.21 |
| COVID-19 SOC | 27 (11.8) | 3 (2.0) | 6.45 (1.92–21.66) | 0.001 |
| IV or SC fluid therapy [n (%)] | 30 (13.2) | 12 (8.2) | 1.70 (0.84–3.45) | 0.09 |
| Oxygen therapy [n (%)] | 19 (8.3) | 14 (9.5) | 0.86 (0.42–1.82) | 0.41 |
| Antibiotic [n (%)] | 24 (10.5) | 10 (6.8) | 1.61 (0.75–3.48) | 0.15 |
| Hospital transfer [n (%)] | 0 (0) | 6 (4.1) | 0.00 (0.00–0.41) | 0.003 |
| Sick leave [n (%)] | 27 (11.8) | 34 (23.1) | 0.45 (0.26–0.78) | 0.004 |
COVID-19 SOC, COVID-19 Standard of care; TID, ter in die or three times a day; IV, intravenous; SC, subcutaneous.
First 3 months after the first confirmed COVID-19 case in each nursing home.
Residents with positive SARS-Cov2 PCR or if residents had positive SARS-Cov serology.
Residents with at least one COVID-19 symptom and at least three ‘confirmed cases’ were diagnosed in the facility.
First 3 weeks after the first confirmed COVID-19 case in each nursing home.
Daily clinical examination by a physician.
Three vital signs measurement a day. Vital signs measurements included blood pressure, pulse, oximetry, respiratory rate and temperature.
Only new prescription of preventive anticoagulation.
COVID-19 Standards of care included preventive anticoagulation, fluid therapy if clinical dehydration and vital signs measurements three times a day.
Demographic, clinical and medical care characteristics among dead or alive presumed and confirmed COVID-19 residents during the first 3 weeks of the outbreak (univariate analysis).
| Characteristics | Dead (n = 28) | Alive (n = 95) | OR (95% CI) | |
|---|---|---|---|---|
| COVID-19 status | ||||
| Confirmed COVID-19 cases | 7 (25.0) | 95 (100) | – | 0.001 |
| Presumed COVID-19 cases | 21 (75.0) | 0 (0) | – | 0.001 |
| Demographical parameters | ||||
| Age [median (IQR)] | 86.5 (77–92) | 87.0 (81–93) | – | 0.27 |
| Female gender [n (%)] | 18 (64.3) | 75 (78.9) | 0.48 (0.19–1.20) | 0.11 |
| Grade of autonomy | ||||
| AGGIR [median (IQR)] | 2.0 (1.0–3.0) | 2,1 (2.0–3.0) | – | 0.54 |
| Nutritional status | ||||
| Obesity | 2 (7.1) | 9 (9.5) | 0.73 (0.14–3.62) | 0.70 |
| Malnutrition | 5 (17.9) | 21 (22.1) | 0.77 (0.26–2.26) | 0.62 |
| Vaccinations | ||||
| Flu vaccination [n (%)] | 22 (78.6) | 83 (87.4) | 0.53 (0.18–1.57) | 0.25 |
| Co-morbidities | ||||
| Arterial hypertension [n (%)] | 15 (53.6) | 57 (60.0) | 0.77 (0.33–1.80) | 0.54 |
| Heart failure [n (%)] | 4 (14.3) | 14 (14.7) | 0.96 (0.29–3.20) | 0.95 |
| Atrial fibrillation [n (%)] | 5 (17.9) | 22 (23.1) | 0.72 (0.25–2.12) | 0.55 |
| Ischaemic heart disease [n (%)] | 2 (7.1) | 9 (9.5) | 0.73 (0.15–3.61) | 0.70 |
| Thromboembolism | 3 (10.7) | 13 (13.7) | 0.76 (0.20–2.87) | 0.68 |
| COPD [n (%)] | 3 (10.7) | 7 (7.4) | 1.51 (0.36–6.26) | 0.56 |
| Active cancer | 0 (0) | 5 (5.3) | 0 (0.00–2.78) | 0.21 |
| Chronic kidney disease [n (%)] | 4 (14.3) | 17 (17.9) | 0.76 (0.23–2.49) | 0.65 |
| Diabetes [n (%)] | 11 (26.8) | 24 (25.3) | 1.91 (0.78–4.65) | 0.15 |
| Co-medications | ||||
| Loop diuretics [n (%)] | 3 (10.7) | 18 (18.9) | 0.51 (0.14–1.89) | 0.31 |
| Thiazide diuretics [n (%)] | 0 (0) | 9 (9.5) | 0 (0.00–1.29) | 0.09 |
| α-Blockers [n (%)] | 1 (3.6) | 7 (7.4) | 0.59 (0.07–4.98) | 0.52 |
| Calcium channel blockers [n (%)] | 7 (25.0) | 24 (25.4) | 0.99 (0.37–2.60) | 0.98 |
| ACE inhibitors or ARB [n (%)] | 6 (21.4) | 20 (21.2) | 1.02 (0.37–2.82) | 0.97 |
| Beta-blockers [n (%)] | 8 (28.6) | 21 (22.1) | 1.40 (0.64–3.65) | 0.48 |
| Insulin [n (%)] | 1 (3.6) | 12 (12.6) | 0.25 (0.03–2.06) | 0.17 |
| Metformin [n (%)] | 3 (10.7) | 5 (5.3) | 2.16 (0.48–9.66) | 0.30 |
ACE, angiotensin converting enzyme; AGGIR, autonomy, gerontology, iso-resources group (autonomies, gerontology groupe iso resources); ARB, angiotensin II receptor blockers; CMD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; IV, intravenous; COVID-19 SOC, COVID-19 Standards of care; SC, subcutaneous; SpO2, peripheral oxygen saturation; TVP, thromboembolic venous disease; TID, ter in die or three times a day.
Confirmed COVID-19 cases if residents had positive SARS-Cov2 PCR or if residents had symptoms and positive SARS-Cov2 serology.
Presumed COVID-19 cases if residents had at least one COVID-19 symptom and at least three ‘confirmed cases’ were diagnosed in the facility.
Defined as body mass index >30.
Defined as body mass index <21 or albumin level <35 g/L.
History of pulmonary embolism or venous thrombosis.
Including both solid and haematological malignancies.
Fever if temperature was >38.3 °C.
Daily clinical examination by a physician.
Three vital signs measurement a day. Vital signs measurements included blood pressure, pulse, oximetry, respiratory rate and temperature.
Only new prescription of preventive anticoagulation.
COVID-19 Standards of care included preventive anticoagulation, fluid therapy if clinical dehydration and vitals measurements three times a day.
Demographic, clinical and medical care characteristics among dead or alive presumed and confirmed COVID-19 residents during the first 3 weeks of the outbreak (multivariate analysis).
| Characteristics | Dead (n = 28) | Alive (n = 95) | Multivariate OR (95% confidence interval) | |
|---|---|---|---|---|
| Age <85 | 13 (46.4) | 31 (32.6) | 1.76 (0.64–4.82) | 0.27 |
| SpO2 < 92% [n (%)] | 16 (55.2) | 21 (22.1) | 4.06 (1.51–10.95) | 0.006 |
| Daily clinical examination [n (%)] | 3 (10.7) | 55 (57.9) | 0.09 (0.03–0.35) | 0.001 |
Residents strictly <85 years old.